Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Pick Your Favored sort of cooking - 2Bomb blast in packed Nigerian mosque kills five
- 3'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
- 4Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- 5NASA says Maven spacecraft that was orbiting Mars has gone silent
- She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- First SpaceX booster for upgraded Starship fails during test in Texas
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- This Week In Space podcast: Episode 186 — Snow on the Moon?
- Help Your Insusceptibility: Good dieting and Way of life Tips
- The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- Jubilant FoodWorks to scrap Dunkin’ franchise arrangement in India
- 5 Breakout Stars in Ongoing television Series
